Publications by authors named "H J Cutuli"
Article Synopsis
- The CheckMate 914 trial investigated the effectiveness of adjuvant nivolumab monotherapy compared to placebo in patients with localized renal cell carcinoma (RCC) at high risk of recurrence after surgery.
- Despite enrolling 825 patients, the results showed that nivolumab did not significantly improve disease-free survival (DFS) compared to placebo.
- Additionally, safety data indicated that adverse events were reported at different rates among the treatment groups, but overall, the trial did not achieve its primary goal of improved DFS for nivolumab.
Article Synopsis
- The evolving oncology treatment landscape shows a need for better administration options that enhance patient experiences and healthcare efficiency.
- A phase III trial (CheckMate 67T) compared subcutaneous nivolumab to intravenous nivolumab in patients with advanced clear cell renal cell carcinoma, focusing on pharmacokinetics and objective response rates.
- Results indicated that subcutaneous nivolumab was noninferior to the intravenous form, showing similar efficacy and safety profiles, with no new safety concerns emerging.
The Impact of Fibroblast Growth Factor Receptor Alterations in Clinical Outcomes of Patients With Advanced Urothelial Carcinoma: Real-World Data From a Latin American Population.
Vinicius Carrera Souza Fernando Sabino Marques Monteiro Fernando Cotait Maluf Gustavo Werutsky Vanessa de Carvalho Fabrício Hernan Javier Cutuli
Clin Genitourin Cancer
October 2024
Article Synopsis
- The study investigates the prevalence of FGFR mutations and fusions in Latino patients with metastatic urothelial carcinoma (mUC), finding these alterations in 17.9% of the analyzed population.
- Despite the presence of FGFR alterations, there was no significant difference in overall survival and time to treatment failure compared to patients without these mutations.
- The research also validates Bellmunt's prognostic model for predicting overall survival in this specific cohort of patients.
Article Synopsis
- * Methods: Researchers analyzed data from 94 patients treated at 29 institutions, assessing various factors like type of therapy, timing of recurrence, and patient risk categories, while also monitoring treatment-related side effects.
- * Key Findings: The study revealed an 18-month PFS rate of 45% and overall survival (OS) rate of 85%, with common treatment-related side effects including skin toxicity and fatigue; it did have limitations due to patient selection.
Article Synopsis
- - The ARON-2 study investigated the real-world effectiveness of pembrolizumab, an immune checkpoint inhibitor, in patients with advanced urothelial carcinoma who had progression after platinum-based chemotherapy, utilizing data from 836 patients across 88 institutions in 23 countries.
- - Results showed median overall survival (OS) of 10.5 months and overall response rate (ORR) of 31%; those who progressed after initial chemotherapy (cohort A) had lower OS (9.1 months) compared to those who recurred within a year post-chemotherapy (cohort B) with 14.6 months OS.
- - Multivariate analysis identified several prognostic factors affecting OS and progression-free survival (PFS),